Is There Any Association Between Mammographic Features of Microcalcifications and Breast Cancer Subtypes in Ductal Carcinoma In Situ?

2020 ◽  
Author(s):  
Aydan Avdan Aslan ◽  
Serap Gültekin ◽  
Güldal Esendağli Yilmaz ◽  
Osman Kurukahvecioğlu
Keyword(s):  
Breast Cancer ◽  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Breast Cancer Subtypes ◽  
Cancer Subtypes

scholarly journals Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study

2016 ◽  
Vol 158 (1) ◽  
pp. 179-187 ◽  
Author(s):  
Shusma C. Doebar ◽  
Esther C. van den Broek ◽  
Linetta B. Koppert ◽  
Agnes Jager ◽  
Margreet. H. A. Baaijens ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Population Based ◽  
Breast Cancer Subtypes ◽  
Cancer Subtypes

Screening mammography-detected ductal carcinoma in situ: mammographic features based on breast cancer subtypes

2015 ◽  
Vol 39 (6) ◽  
pp. 983-986 ◽  
Author(s):  
Mi Young Kim ◽  
Hyeon Sook Kim ◽  
Nami Choi ◽  
Jung-Hyun Yang ◽  
Young Bum Yoo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Screening Mammography ◽  
Breast Cancer Subtypes ◽  
Cancer Subtypes

scholarly journals The Emerging Roles of Steroid Hormone Receptors in Ductal Carcinoma in Situ (DCIS) of the Breast

2018 ◽  
Vol 23 (4) ◽  
pp. 237-248 ◽  
Author(s):  
Hugo Villanueva ◽  
Sandra Grimm ◽  
Sagar Dhamne ◽  
Kimal Rajapakshe ◽  
Adriana Visbal ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Hormone Receptors ◽  
Ductal Carcinoma ◽  
Clinical Problem ◽  
Experimental Models ◽  
Steroid Hormone Receptors ◽  
Cancer Risk Factors

Abstract Ductal carcinoma in situ (DCIS) is a non-obligate precursor to most types of invasive breast cancer (IBC). Although it is estimated only one third of untreated patients with DCIS will progress to IBC, standard of care for treatment is surgery and radiation. This therapeutic approach combined with a lack of reliable biomarker panels to predict DCIS progression is a major clinical problem. DCIS shares the same molecular subtypes as IBC including estrogen receptor (ER) and progesterone receptor (PR) positive luminal subtypes, which encompass the majority (60–70%) of DCIS. Compared to the established roles of ER and PR in luminal IBC, much less is known about the roles and mechanism of action of estrogen (E2) and progesterone (P4) and their cognate receptors in the development and progression of DCIS. This is an underexplored area of research due in part to a paucity of suitable experimental models of ER+/PR + DCIS. This review summarizes information from clinical and observational studies on steroid hormones as breast cancer risk factors and ER and PR as biomarkers in DCIS. Lastly, we discuss emerging experimental models of ER+/PR+ DCIS.

scholarly journals Different Biological Action of Oleic Acid in ALDHhigh and ALDHlow Subpopulations Separated from Ductal Carcinoma In Situ of Breast Cancer

PLoS ONE ◽  
2016 ◽  
Vol 11 (9) ◽  
pp. e0160835
Author(s):  
Hoe Suk Kim ◽  
Minji Jung ◽  
Sul Ki Choi ◽  
Woo Kyung Moon ◽  
Seung Ja Kim
Keyword(s):  
Breast Cancer ◽  
Oleic Acid ◽  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Biological Action
Sign in / Sign up

Export Citation Format

Share Document